Genomic Health to Participate in Leerink Swann Roundtable Conference
Posted on: Friday, 28 March 2008, 09:01 CDT
REDWOOD CITY, Calif., March 28 /PRNewswire-FirstCall/ -- Genomic Health, Inc. today announced that Steven Shak, M.D., Genomic Health's Chief Medical Officer, will participate in Leerink Swann's Roundtable Conference, Bugs and Drugs: The Future of Molecular Diagnostics, in New York, NY on April 3, 2008 at 11:30 a.m. Eastern Time.
To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website at http://investor.genomichealth.com/. Please connect to the website at least 15 minutes prior to the beginning of the presentation to allow for any necessary software downloads. An archived replay will be available for three months beginning 24 hours after the live presentation.
About Genomic Health
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com/
Genomic Health, Inc.
CONTACT: investors, Brad Cole, +1-650-569-2281,investors@genomichealth.com, or media, Emily Faucette, +1-650-569-2824,media@genomichealth.com, both of Genomic Health
Web site: http://www.genomichealth.com/
Source: PRNewswire-FirstCall
Related Articles
- Genomic Health to Present Five New Studies at 32nd Annual San Antonio Breast Cancer Symposium
- Genomic Health to Present Studies at the American Society of Clinical Oncology 2009 Breast Cancer Symposium
- Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
- Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
- Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
- Genomic Health Announces New Data on Oncotype DX(TM) to Be Presented at 29th Annual San Antonio Breast Cancer Symposium
- Genomic Health to Present at UBS Global Life Sciences Conference
- Genomic Health, Inc. Announces Positive Results in Multiple Studies Presented at the American Society of Clinical Oncology Meeting
- Genomic Health Announces 'Early Release' Publication of NSABP Study Confirming Oncotype DX Predicts Chemotherapy Benefit in Certain Breast Cancer Patients; Study Findings Pave Way for Landmark NCI TAILORx Trial
- Genomic Health Announces Oncotype DX(TM) Study Results to Be Presented at 28th Annual San Antonio Breast Cancer Symposium
 |
 |
User Comments (0)
RSS Feeds